NYSE:TAK Takeda Pharmaceutical (TAK) Stock Price, News & Analysis $20.85 -0.08 (-0.40%) Closing price 03:59 PM EasternExtended Trading$21.12 +0.27 (+1.29%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Takeda Pharmaceutical Stock (NYSE:TAK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Takeda Pharmaceutical alerts:Sign Up Key Stats Today's Range$20.68▼$20.8650-Day Range$17.83▼$21.2452-Week Range$13.91▼$21.73Volume1.96 million shsAverage Volume3.15 million shsMarket Capitalization$66.80 billionP/E Ratio11.96Dividend Yield2.30%Price TargetN/AConsensus RatingBuy Company Overview Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas. Takeda serves patients and healthcare providers in Japan and markets around the world. Its operations span research and development, manufacturing and commercial activities, with a focus on bringing treatments to patients with serious and often complex health conditions.AI Generated. May Contain Errors. Read More Takeda Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreTAK MarketRank™: 3.256544502615 of 5 starsTakeda Pharmaceutical scored higher than 65% of companies evaluated by MarketBeat, and ranked 295th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingBuy Consensus RatingTakeda Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTakeda Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Takeda Pharmaceutical's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-10.26% Earnings GrowthEarnings for Takeda Pharmaceutical are expected to decrease by -10.26% in the coming year, from $1.56 to $1.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Takeda Pharmaceutical is 11.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Takeda Pharmaceutical is 11.96, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.36.Price to Book Value per Share RatioTakeda Pharmaceutical has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Takeda Pharmaceutical's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.10% of the float of Takeda Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverTakeda Pharmaceutical has a short interest ratio ("days to cover") of 1.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Takeda Pharmaceutical has recently decreased by 6.77%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldTakeda Pharmaceutical pays a meaningful dividend of 2.30%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthTakeda Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Takeda Pharmaceutical is 63.16%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 34.29% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.Read more about Takeda Pharmaceutical's dividend. News and Social Media3.7 / 5News Sentiment0.95 News SentimentTakeda Pharmaceutical has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Takeda Pharmaceutical this week, compared to 3 articles on an average week.Search Interest3 people have searched for TAK on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Takeda Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,549,461.00 in company stock.Percentage Held by Insiders0.04% of the stock of Takeda Pharmaceutical is held by insiders.Percentage Held by Institutions9.17% of the stock of Takeda Pharmaceutical is held by institutions.Read more about Takeda Pharmaceutical's insider trading history. Receive TAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TAK Stock News HeadlinesTakeda Pharmaceutical (NYSE:TAK) Stock: Insider Giles Richard Platford Sells 55,617 SharesNovember 7, 2026 | americanbankingnews.comInsider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $1,162,395.30 in StockNovember 6, 2026 | insidertrades.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 11 at 1:00 AM | Paradigm Press (Ad)Takeda Pharmaceutical (NYSE:TAK) Sets New 1-Year High After Earnings BeatNovember 1, 2026 | americanbankingnews.comTakeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash FlowOctober 30, 2026 | seekingalpha.comTakeda Beats Earnings Forecasts and Hikes Outlook Despite Generic OverhangOctober 29, 2026 | benzinga.comTakeda Pharmaceutical Company Limited reports revenue of 2,406,997 million JPY for the six-month period ended September 30, 2026October 29, 2026 | msn.comTakeda Pharmaceutical Company Limited H1 Profit ClimbsOctober 29, 2026 | rttnews.comSee More Headlines TAK Stock Analysis - Frequently Asked Questions How have TAK shares performed this year? Takeda Pharmaceutical's stock was trading at $15.59 on January 1st, 2026. Since then, TAK stock has increased by 33.7% and is now trading at $20.8470. How were Takeda Pharmaceutical's earnings last quarter? Takeda Pharmaceutical Co. (NYSE:TAK) released its quarterly earnings results on Thursday, July, 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.41 by $0.54. The business had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a net margin of 8.26% and a trailing twelve-month return on equity of 11.51%. Read the conference call transcript. Does Takeda Pharmaceutical have any subsidiaries? Takeda Pharmaceutical subsidiaries include PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and others. Who are Takeda Pharmaceutical's major shareholders? Top institutional shareholders of Takeda Pharmaceutical include Crossmark Global Holdings Inc. (0.02%), Ethic Inc. (0.01%), Hantz Financial Services Inc. (0.01%) and Russell Investments Group Ltd. (0.01%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Julie So-Young Kim, Giles Richard Platford, Natalie Anne Marie Furney, Lauren Rusckowski Duprey, Agosti Marcello Pignagnoli, Gabriele Ricci, Andrew Stewart Plump, Awny Samaan Botros Farajallah, Ramy Riad Ahmed Ibrahim, Elaine Mary Shannon and Nicola Deidre Petal Greenway. View institutional ownership trends. How do I buy shares of Takeda Pharmaceutical? Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include NVIDIA (NVDA), Pfizer (PFE), Verizon Communications (VZ), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings7/30/2026Today11/11/2026Investor Day 202612/10/2026Next Earnings (Estimated)1/28/2027Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TAK's financial health is in the Green zone, according to TradeSmith. TAK has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:TAK CIK1395064 Webwww.takeda.com Phone+81332782111Fax813-3278-2268Employees47,000Year Founded1781Profitability EPS (Trailing Twelve Months)$0.76 Trailing P/E Ratio11.96 Forward P/E Ratio14.89 P/E GrowthN/ANet Income-$1.01 billion Net Margins8.26% Pretax Margin-3.16% Return on Equity11.51% Return on Assets5.59% Debt Debt-to-Equity Ratio0.56 Current Ratio1.15 Quick Ratio0.60 Sales & Book Value Annual Sales$28.32 billion Price / Sales2.36 Cash Flow$3.09 per share Price / Cash Flow6.74 Book Value$14.58 per share Price / Book1.43Miscellaneous Outstanding Shares3,204,440,000Free Float3,203,155,000Market Cap$66.80 billion OptionableOptionable Beta-0.02 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NYSE:TAK) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TAK Stock Alerts